13 Best American Dividend Stocks to Buy According to Analysts

7. Eli Lilly and Company (NYSE:LLY)

Upside Potential as of April 20: 21.3%

Eli Lilly and Company (NYSE:LLY) ranks seventh on our list of the best dividend stocks according to analysts. In recent years, weight loss medications have emerged as a key growth driver for the pharmaceutical sector, and Eli Lilly’s entry into the GLP-1 space has proven to be highly successful. Beyond its work with GLP-1 drugs, the company is also seeing strong momentum with its cancer treatment, Verzenio. With multiple FDA approvals under its belt, Verzenio is helping the company expand its presence in the oncology field. Since the start of 2025, the stock has surged by nearly 8%.

According to analysts, another promising area for Eli Lilly and Company (NYSE:LLY) is the treatment of Alzheimer’s disease (AD), a market projected to reach tens of billions of dollars in the coming years. Despite its size, the AD market remains fragmented, with limited competition and many treatments targeting only specific symptoms. In the summer of last year, Lilly secured FDA approval for its AD drug, Kisunla. While weight loss therapies are expected to remain the company’s primary revenue driver in the near term, the long-term growth potential of Kisunla should not be overlooked, especially as Lilly expands its presence in the Alzheimer’s space.

In addition to its strong pipeline of products, Eli Lilly and Company (NYSE:LLY) also holds a solid dividend history. The company has been rewarding shareholders with growing dividends for the past 11 years. It currently offers a quarterly dividend of $1.50 per share and has a dividend yield of 0.71%, as of April 20.